VAXXCellence SRL
VAXXCellence reported total assets of 148,132 € at the end of the 2025 financial year (annual accounts filed with the NBB on 03 Jul 2026).
The score of VAXXCellence shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
VAXXCellence's annual accounts
| 2025 | |
|---|---|
| Net result | 88,139 € |
| Equity | 103,139 € |
| Cash | 68,211 € |
| EBITDA | 126,643 € |
| Total assets | 148,132 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 03 Jul 2026
VAXXCellence's financial analysis
- Solvency69.6%sector median: 60.4%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of VAXXCellence
VAXXCellence's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1010.780.382
- VAT number
- BE1010780382
- Peppol
- Registered · 0208:1010780382 · as of 11 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Jun 2024
- Registered office
- 2000 Antwerp
- Latest accounts
- 2025 · filed on 03 Jul 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
VAXXCellence (SRL) has been based in Antwerp since 2024, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net profit of 88,139 € and equity of 103,139 €; its revenue is not published. Its solvency stands at 69.6%, above the median of its sector (60.4%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to VAXXCellence
Companies in the same business, of comparable size and area, outside its group.
- Digital Cell Imaging Labs Research and experimental development on natural sciences and engineering Keerbergen · balance sheet 136,708 €
- Artlinow Research and experimental development on natural sciences and engineering Lasne · balance sheet 156,662 €
- ResiResearch Research and experimental development on natural sciences and engineering Anderlecht · balance sheet 165,690 €
- Arhea Research and experimental development on natural sciences and engineering Tongeren-Borgloon · balance sheet 171,716 €
- Emelie Flemming-Parker Research and experimental development on natural sciences and engineering Tongeren-Borgloon · balance sheet 114,901 €
- Arethe Research and experimental development on natural sciences and engineering Ixelles · balance sheet 124,920 €
- Société Médicale Dr VAN DURME Research and experimental development on natural sciences and engineering Liège · balance sheet 121,781 €
- Teams Creations Research and experimental development on natural sciences and engineering Soignies · balance sheet 111,271 €
Frequently asked questions about VAXXCellence
What is the revenue of VAXXCellence?
VAXXCellence files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of VAXXCellence?
In Belgium, the VAT number is the company number prefixed with BE: BE1010780382 for VAXXCellence, if the company is VAT-registered. Its company number (CBE) is 1010.780.382.
Where is the registered office of VAXXCellence?
According to the CBE register, the registered office of VAXXCellence is in 2000 Antwerp.
What is the equity of VAXXCellence?
At the close of the 2025 financial year, the equity of VAXXCellence amounts to 103,139 €, a solvency of 69.6% of total assets.
Who manages VAXXCellence?
The register lists 1 active mandates at VAXXCellence. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of VAXXCellence
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →